Andere talen Nuvectis Pharma, Inc.

Aandelen

NVCT

US67080T1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,45 ^USD	-5,84%		-2,71%	-22,66%

07/05	Nuvectis Pharma, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
08/04	Nxp900 van Nuvectis Pharma toont robuuste activiteit aan in niet-kleincellige longkankercellijnen	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Precision Medicine M&A is Transforming the Future of the Biotech Industry	17/06
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference	16/05
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights	07/05
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08/04
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08/04
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08/04
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting	19/03
Nuvectis Pharma to Present at the 36th Annual Roth Conference	15/03
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer	14/03
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer	14/03
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	14/03
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights	05/03
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences	09/02
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences	09/02
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma	18/12
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nuvectis Pharma, Inc.

Aandelen

NVCT

US67080T1088

Andere talen

Filters